Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Hepatic MRI with SPIO: detection and characterization of focal liver lesions (1998)
    Springer
    European radiology 8 (1998), S. 1198-1204 
    Details
    ISSN: 1432-1084
    Keywords: Key words: Iron oxides ; Liver ; SPIO ; USPIO
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. A variety of parenterally administered iron oxides have been developed for contrast-enhanced MRI of the liver. Two different classes of iron oxides are currently clinically approved or in phase 3 trials: superparamagnetic iron oxides (SPIO) with a high R2/R1 relaxivity ratio and short blood half-life (AMI-25 and SH U 555 A), and ultrasmall paramagnetic iron oxides (USPIO) with a lower R2/R1 relaxivity ratio and longer blood half-life (AMI-227). All iron oxides significantly increase tumor-to-liver contrast and allow detection of more lesions than unenhanced MRI on T2-weighted images at a field strength of 0.2–1.5 T. Malignant lesions without phagocytic cells exhibit constant signal on T2-weighted accumulation phase images with all three iron oxides. All iron oxides cause a signal decrease of benign lesions with either phagocytic cells or a significant blood pool on T2-weighted accumulation phase images. The signal decrease of benign lesions is proportional to the Kupffer cell activity or tumor vascularity and is useful for lesion characterization. Another enhancement feature for the differentiation of benign from malignant lesions is ring enhancement of malignant lesions (metastases) on T1-weighted enhanced images either during the perfusion phase with SH U 555 A or during the accumulation phase with AMI-227, which is attributed to the blood pool effects of the compounds. Differentiation of lesions and vessels is easier on enhanced images with angiographic effects than on unenhanced images. Iron oxides improve the quality of two-dimensional MR angiography techniques of the portal venous system by decreasing background signal (liver tissue with all iron oxides) and increasing intravascular signal (AMI-227). The use of iron oxides for hepatic MRI provides an alternative to the existing multistep diagnosis with CT, CT portography, MRI and biopsy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s003300050535
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging (1997)
    Springer
    European radiology 7 (1997), S. 275-280 
    Details
    ISSN: 1432-1084
    Keywords: Key words: MRI ; Liver ; Gd-EOB-DTPA ; Characterization
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. Our objective was to study Gd-EOB-DTPA for the characterization of focal liver lesions by means of dynamic MR imaging. A double-blind and randomized dose-ranging phase-2 clinical trial was performed in 31 patients (liver metastases n = 23, hepatocellular carcinoma n = 4, and hemangioma n = 4) at a field strength of 1.0 Tesla. Gd-EOB-DTPA (Schering AG, Berlin, Germany) was administered as an IV bolus (12.5, 25, or 50 μmol/kg body weight) with dynamic T1-weighted MRI during the distribution and cellular uptake of the contrast agent at multiple time points up to 45 min post contrast. Dynamic changes in tumor signal intensity, tumor–liver contrast, enhancement patterns, side effects, and adverse events were evaluated. Monitoring of vital signs revealed no significant changes during bolus injection of Gd-EOB-DTPA. Liver metastases demonstrated an inhomogeneous uptake of Gd-EOB-DTPA during the distribution phase with a washout effect on delayed images 〉 3 min and highest tumor–liver contrast 20 and 45 min post contrast. Hepatocellular carcinomas showed prolonged enhancement as compared with metastases and hemangiomas. Hemangiomas exhibited an early peripheral–nodular enhancement with subsequent partial or complete filling, persisting enhancement 〈 10 min following injection of Gd-EOB-DTPA, and delayed washout as compared with liver metastases. Initial clinical experience suggests that Gd-EOB-DTPA as a bolus injectable hepatobiliary MR contrast agent may offer useful features for the characterization of focal liver lesions.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s003300050150
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Purification of human placental prostaglandin 15-hydroxydehydrogenase
    Amsterdam : Elsevier
    Journal of Chromatography A 521 (1990), S. 231-238 
    Details
    ISSN: 0021-9673
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://linkinghub.elsevier.com/retrieve/pii/0021-9673(90)85047-Y
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Neue MR-Kontrastmittel in der Leberdiagnostik Erste klinische Ergebnisse mit hepatobiliärem Eovist® (Gadolinium-EOB-DTPA) und RES-spezifischem Resovist® (SH U 555 A) (1996)
    Springer
    Der Radiologe 36 (1996), S. 124-133 
    Details
    ISSN: 1432-2102
    Keywords: Schlüsselwörter Leber ; MRT ; Kontrastmittel ; Resovist® ; Eovist® ; Key words Liver ; MRI ; Contrast agents ; Resovist ; Eovist
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary The purpose of this work is to describe our initial clinical experience (in 66 patients) with Resovist and Eovist, two new liver-specific MR contrast agents. We focus our report on safety aspects, dose finding, and optimization of technical parameters. Both contrast agents were well tolerated and improved the detectability of focal liver lesions. With Resovist, postcontrast MRI may be started as early as 10 min following injection. The dose of 8 μmol Fe/kg bodyweight was sufficient to achieve diagnostic tumor-liver contrast levels. Since Eovist can also be administered as a bolus, dynamic enhance- ment patterns may be studied for tumor characterization as well. Breath-hold T 1-weighted FLASH images were superior to other T 1-weighted techniques with and without fat saturation.
    Notes: Zusammenfassung In der vorliegenden Arbeit werden erste klinische Ergebnisse (66 Patienten) der für die Leberbildgebung entwickelten Kontrastmittel Resovist® und Eovist® vorgestellt. Es wurden Sicherheitsaspekte, Dosierungsfragen und die optimale Untersuchungstechnik am Beispiel fokaler Leberläsionen untersucht. Beide „leberspezifischen“ Kontrastmittel zeigten bei guter Verträglichkeit eine Verbesserung des Nachweises fokaler Leberläsionen. Die Untersuchung mit Resovist® kann bereits 10 min nach der Kontrastmittelinjektion erfolgen. Mit einer Dosis von 8 μmol Fe/kg Körpergewicht konnte eine ausreichender Tumor-Leber-Kontrast erzielt werden. Da Eovist® zusätzlich im Bolus injiziert werden kann, ergeben sich neben dem Nachweis fokaler Leberläsionen Möglichkeiten der Charakterisierung durch Analyse der Perfusionsmuster. Atemgehaltene T 1-gewichtete FLASH-Sequenzen waren sonstigen T 1-gewichteten Sequenzen ohne und mit Fettgesättigung überlegen.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001170050049
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...